NAT10 and neoplasm: Impressively, NAT10 knockdown acted synergistically with PD‐L1 blockade therapy in vivo, leading to tumor regression by impairing tumor cell glycolysis, decreasing lactic acid production, attenuating immunosuppression and improving immunosurveillance (as shown in the Graphical Abstract).